BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26770245)

  • 1. Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
    Marcheselli R; Marcheselli L; Cortesi L; Bari A; Cirilli C; Pozzi S; Ferri P; Napolitano M; Federico M; Sacchi S
    J Breast Cancer; 2015 Dec; 18(4):378-85. PubMed ID: 26770245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
    Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
    Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
    Gaffney DK; Hemmersmeier J; Holden J; Marshall J; Smith LM; Avizonis V; Tran T; Neuhausen SL
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):539-46. PubMed ID: 11173152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
    Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second malignant neoplasms in digestive organs after childhood cancer: a cohort-nested case-control study.
    Tukenova M; Diallo I; Anderson H; Hawkins M; Garwicz S; Sankila R; El Fayech C; Winter D; Rubino C; Adjadj E; Haddy N; Oberlin O; Moller T; Langmark F; Tryggvadottir L; Pacquement H; Svahn-Tapper G; de Vathaire F
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e383-90. PubMed ID: 22284034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
    Haffty BG; Harrold E; Khan AJ; Pathare P; Smith TE; Turner BC; Glazer PM; Ward B; Carter D; Matloff E; Bale AE; Alvarez-Franco M
    Lancet; 2002 Apr; 359(9316):1471-7. PubMed ID: 11988246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    Gargiulo P; Pensabene M; Milano M; Arpino G; Giuliano M; Forestieri V; Condello C; Lauria R; De Placido S
    BMC Cancer; 2016 Jul; 16():375. PubMed ID: 27377827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.
    Ottini L; Rizzolo P; Zanna I; Falchetti M; Masala G; Ceccarelli K; Vezzosi V; Gulino A; Giannini G; Bianchi S; Sera F; Palli D
    Breast Cancer Res Treat; 2009 Aug; 116(3):577-86. PubMed ID: 18819001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Gronwald J; Lynch HT; Eisen A; Neuhausen SL; Tung N; Ainsworth P; Weitzel JN; Pal T; Foulkes WD; Eng C; Singer CF; Senter L; Sun P; Lubinski J; Narod SA;
    Breast Cancer Res Treat; 2018 Sep; 171(2):421-426. PubMed ID: 29774471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
    Badora A; Kaleta B; Nowara E; Sikora-Jopek M; Budryk M; Smok-Ragankiewicz A
    Ginekol Pol; 2013 Oct; 84(10):892-6. PubMed ID: 24273914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
    Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.